- Trials with a EudraCT protocol (100)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
100 result(s) found for: Endometrial tissue.
Displaying page 1 of 5.
| EudraCT Number: 2019-001447-40 | Sponsor Protocol Number: 28UCS2019 | Start Date*: 2020-06-29 | ||||||||||||||||
| Sponsor Name:ENTE OSPEDALIERO OSPEDALI GALLIERA | ||||||||||||||||||
| Full Title: Pilot Study of Daily Exemestane in Women with Complex Atypical Hyperplasia of the Endometrium / Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer | ||||||||||||||||||
| Medical condition: Complex Atypical Hyperplasia of the Endometrium / Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer in post-menopausal women | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
| Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2011-001382-40 | Sponsor Protocol Number: Metform01 | Start Date*: 2011-09-09 | |||||||||||
| Sponsor Name:Central Manchester University Hospitals NHS Foundation Trust | |||||||||||||
| Full Title: Proof of mechanism pre-surgical window trial of metformin in non-diabetic women with endometrial carcinoma: a feasibility study | |||||||||||||
| Medical condition: Endometrial carcinoma or hyperplasia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-001434-29 | Sponsor Protocol Number: VX-EC-2-2013 | Start Date*: 2015-01-13 | |||||||||||||||||||||
| Sponsor Name:AS Kevelt | |||||||||||||||||||||||
| Full Title: A Phase II Study of Sodium Cridanimod in Conjunction with Progestin Therapy in Patients with Progesterone Receptor Negative Recurrent or Persistent Endometrial Carcinoma. | |||||||||||||||||||||||
| Medical condition: PrR negative papillary serous adenocarcinoma, endometroid type of endometrial carcinoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
| Trial protocol: CZ (Completed) SK (Completed) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2009-010613-68 | Sponsor Protocol Number: X-55-58064-004 | Start Date*: 2009-07-06 | |||||||||||
| Sponsor Name:Ipsen Pharma | |||||||||||||
| Full Title: A phase II international multicentre randomised open label study of oral steroid sulphatase inhibitor BN83495 versus megestrol acetate (MA) in women with advanced or recurrent endometrial cancer | |||||||||||||
| Medical condition: Advanced or recurrent endometrial cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: BE (Completed) GB (Completed) FR (Completed) ES (Prematurely Ended) CZ (Completed) HU (Completed) PL (Completed) LT (Completed) LV (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-003469-32 | Sponsor Protocol Number: UCL/13/0045 | Start Date*: 2014-10-13 | |||||||||||
| Sponsor Name:University College London | |||||||||||||
| Full Title: A Single Arm Phase II trial of BMN 673 for inoperable, advanced endometrial cancer with retrospective PTEN, MSI and MRE11 analysis. | |||||||||||||
| Medical condition: Inoperable, advanced, recurrent or metastatic endometrial cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: GB (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-004403-31 | Sponsor Protocol Number: MITOEND-3 | Start Date*: 2022-03-24 | |||||||||||
| Sponsor Name:ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE | |||||||||||||
| Full Title: MITO END-3: A randomized phase II trial of Carboplatin+Paclitaxel compared to Carboplatin+Paclitaxel+Avelumab in advanced (stage III-IV) or recurrent endometrial cancer | |||||||||||||
| Medical condition: advanced (stage III-IV) or recurrent endometrial cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-005717-40 | Sponsor Protocol Number: 2001-FIVI-002-IC | Start Date*: 2021-05-05 |
| Sponsor Name:IVI Foundation | ||
| Full Title: Umbilical cord plasma for treating endometrial pathologies (thin endometrium / Ash erman’s syndrome/ endometria atrophy) | ||
| Medical condition: Endometrial pathologies (Thin endometrium/ Asherman's syndrome/ Endometrial atrophy) | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2016-004617-28 | Sponsor Protocol Number: | Start Date*: 2017-11-30 | |||||||||||
| Sponsor Name:The University of Manchester | |||||||||||||
| Full Title: A 3-Arm Randomised Phase II Evaluation of Cediranib in Combination with Weekly Paclitaxel or Olaparib Versus Weekly Paclitaxel Chemotherapy as Second-Line Therapy for Advanced/Metastatic Endometria... | |||||||||||||
| Medical condition: Advanced or recurrent endometrial carcinoma or carcinosarcoma | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-001352-21 | Sponsor Protocol Number: ABT-C5-2016 | Start Date*: 2016-09-19 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Ability Pharmaceuticals, SL | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A phase I/ II, open label study to assess the efficacy and safety of ABTL0812 in combination with paclitaxel and carboplatin in patients with advanced endometrial cancer or squamous NSCLC | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Squamous Cell Non-Small Cell Lung Cancer and advanced endometrial cancer | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: ES (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2014-002352-12 | Sponsor Protocol Number: OTL-038 | Start Date*: 2014-08-18 | |||||||||||||||||||||
| Sponsor Name:On Target Laboratories , LLC | |||||||||||||||||||||||
| Full Title: A Single Ascending Dose, Open Label, Exploratory Study of OTL-038 for the Intra-operative Imaging of Folate Receptor Alpha Positive Ovarian, Renal Cell and Endometrial Cancer | |||||||||||||||||||||||
| Medical condition: Primary ovarian cancer planned for either primary debulking surgery or interval debulking surgery by laparotomy or planned for surgical staging by laparoscopy. Primary renal cell carcinoma planned... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: NL (Completed) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2021-004061-13 | Sponsor Protocol Number: ESR21-21165 | Start Date*: 2022-06-09 | ||||||||||||||||
| Sponsor Name:VHIO Vall d’Hebron Institute of Oncology | ||||||||||||||||||
| Full Title: Single cell characterization of persistent cells upon treatment with durvalumab (MEDI4736) with or without tremelimumab in MSS and MSI colorectal and endometrial tumors | ||||||||||||||||||
| Medical condition: MSS and MSI colorectal and endometrial tumors | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: ES (Ongoing) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2020-000496-20 | Sponsor Protocol Number: INCMGA0012-204 | Start Date*: 2021-01-08 | ||||||||||||||||
| Sponsor Name:Incyte Corporation | ||||||||||||||||||
| Full Title: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemothe... | ||||||||||||||||||
| Medical condition: Endometrial cancer | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
| Trial protocol: FR (Trial now transitioned) DE (Prematurely Ended) BE (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2010-024396-12 | Sponsor Protocol Number: CBEZ235C2201 | Start Date*: 2011-06-13 | |||||||||||
| Sponsor Name:Novartis Pharma Services AG | |||||||||||||
| Full Title: A Phase II, single-arm study of orally administered BEZ235 as second-line therapy in patients with advanced endometrial carcinoma | |||||||||||||
| Medical condition: Patients who have experienced progression of disease after first-line antineoplasic treatment of advanced endometrial carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: CZ (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-000607-25 | Sponsor Protocol Number: KCP-330-024BGOG-EN5/ENGOT-EN5/SIEND | Start Date*: 2017-11-22 | |||||||||||||||||||||
| Sponsor Name:Karyopharm Therapeutics Inc. | |||||||||||||||||||||||
| Full Title: A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer | |||||||||||||||||||||||
| Medical condition: Selinexor/placebo will be given as maintenance therapy after combination chemotherapy for patients with advanced endometrial cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||||||||||||
| Trial protocol: BE (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) PL (Completed) IT (Trial now transitioned) GR (Trial now transitioned) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2011-000266-35 | Sponsor Protocol Number: CTKI258A2211 | Start Date*: 2012-03-21 | |||||||||||
| Sponsor Name:NOVARTIS FARMA | |||||||||||||
| Full Title: A phase II, open-label, single-arm, non-randomized, multi-center study to evaluate the efficacy of oral TKI258 as second-line therapy in patients with either FGFR2 mutated or wild-type advanced and... | |||||||||||||
| Medical condition: Advanced and/or metastatic endometrial carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) ES (Completed) GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-003009-24 | Sponsor Protocol Number: MK-7902-001 | Start Date*: 2020-03-18 | |||||||||||
| Sponsor Name:Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. | |||||||||||||
| Full Title: A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-... | |||||||||||||
| Medical condition: Advanced Endometrial Cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: AT (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) DE (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-001624-17 | Sponsor Protocol Number: 210321 | Start Date*: 2021-07-21 |
| Sponsor Name:Karolinska University Hospital | ||
| Full Title: Safety of oral micronized progesterone versus norethisterone acetate in continuous combination with oral estrogen as menopausal hormone therapy – a double-blind randomized study- PROBES study (Prog... | ||
| Medical condition: Climacteric symptoms | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: SE (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2014-000070-19 | Sponsor Protocol Number: CRUKD/14/001 | Start Date*: 2015-06-19 | ||||||||||||||||||||||||||
| Sponsor Name:Cancer Research UK | ||||||||||||||||||||||||||||
| Full Title: A Cancer Research UK Phase I Study of MOv18 IgE, a first in class chimeric IgE antibody against folate receptor-α, in patients with advanced solid tumours | ||||||||||||||||||||||||||||
| Medical condition: Advanced unresectable solid tumour of a type known to express folate receptor alpha (FRα) in a percentage of cases for which no alternative therapy is felt to be appropriate. | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2010-022015-19 | Sponsor Protocol Number: CBKM120C2201 | Start Date*: 2011-04-26 | |||||||||||
| Sponsor Name:Novartis Farmacéutica, S.A | |||||||||||||
| Full Title: Estudio de fase II, de una sola rama, de BKM120 administrado por vía oral como tratamiento de segunda línea en pacientes con carcinoma endometrial avanzado | |||||||||||||
| Medical condition: Mujeres adultas con carcinoma endometrial avanzado cuya enfermedad ha progresado durante o después del tratamiento antineoplásico de primera línea para la enfermedad avanzada. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: ES (Prematurely Ended) BE (Completed) DE (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-004364-11 | Sponsor Protocol Number: 69HCL15_0321 | Start Date*: 2016-03-07 | |||||||||||
| Sponsor Name:Hospices Civils de Lyon | |||||||||||||
| Full Title: ENDOLA A PHASE I/II TRIAL TO ASSESS THE SAFETY AND EFFICACY OF METRONOMIC CYCLOPHOSPHAMIDE, METFORMIN AND OLAPARIB IN RECURRENT ADVANCED/METASTATIC ENDOMETRIAL CANCER PATIENTS | |||||||||||||
| Medical condition: - Patients with histologically and/or cytologically documented endometrial carcinoma (type I or type II), recurrent after platinum-based chemotherapy | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
